The FDA Panel Voted Yes on BPC-157 and KPV. Compounding Is Still Not Legal Today.

On Thursday July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted 8-6 with one abstention to recommend that BPC-157 be added to the Section 503A bulk drug substances list. About an hour later, the same panel voted 8-6 with one abstention to recommend KPV. Both peptides had gone into the meeting with FDA career-staff briefing documents recommending against inclusion.

The stock market read the vote as a clear win. Hims & Hers (NYSE: HIMS) shares surged 10-13% intraday. Time Magazine ran a same-day analysis headlined 'An FDA committee just voted in favor of peptides, despite the agency's opposition.' STAT News called it a win for HHS Secretary Robert F. Kennedy Jr.

The read from a legal and practical standpoint is different. A PCAC vote is a recommendation to the FDA. The FDA still has to decide whether to accept the recommendation, and if it does, has to run a formal rulemaking process to actually add BPC-157 and KPV to the 503A list. Rulemaking of this type typically takes 6 to 18 months from the date the FDA decides to act. Until that process is complete and published in the Federal Register, compounding pharmacies still cannot legally prepare BPC-157 or KPV under the Section 503A pathway.

This piece walks through what the vote actually is, what Section 503A actually is, why the vote passed against the career-staff recommendation, what has to happen next, what compounding pharmacies can and cannot do today, and how to think about peptide-clinic offers in the coming months.

The Pharmacy Compounding Advisory Committee (PCAC) is a formal FDA advisory committee. It reviews substances that pharmacists want to compound (make in a pharmacy under a prescription) but that are not FDA-approved as commercial drug products. When PCAC meets, it votes on whether individual substances belong on one of two lists:

• Section 503A bulk drug substances list: substances that state-licensed pharmacists can use to compound drugs for individual patients under a prescription
• Section 503B bulk drug substances list: substances that federally-registered outsourcing facilities (larger-scale compounders) can use

PCAC votes are non-binding. The committee's recommendation goes to the FDA, and FDA leadership decides whether to follow it. In practice, the FDA usually follows PCAC recommendations, but there is no legal requirement to do so. The agency can accept, modify, or reject any PCAC vote.

The July 23-24, 2026 meeting reviewed seven research peptides that had been removed from FDA Category 2 in April 2026: BPC-157, KPV, TB-500, MOTS-c on Day 1; DSIP (also called Emideltide), Semax, and Epitalon on Day 2. The written comment docket for the meeting (FDA-2025-N-6895) closed at 11:59 PM ET on July 22 with approximately 1,860 public comments filed.

The committee that voted on July 23 included eight new members named by the FDA on June 29. STAT News reported that at least seven of the eight new members have documented ties to peptide-related businesses, clinics, or consulting arrangements. That composition change was the subject of criticism from consumer-safety groups (Public Citizen, Institute for Safe Medication Practices, Partnership for Safe Medicines) in the run-up to the vote.

Section 503A is a section of the Federal Food, Drug, and Cosmetic Act that governs pharmacy compounding. Under 503A, a licensed pharmacist can prepare a compounded drug for an individual patient under a valid prescription without needing FDA approval of the compounded drug itself.

There are limits. A compounded drug under 503A must be made from one of two sources of ingredients:

1. A bulk drug substance that is listed as a component of an FDA-approved drug product, or
2. A bulk drug substance that appears on the 503A bulks list because the FDA (after PCAC review) has affirmatively added it

BPC-157 and KPV do not appear in any FDA-approved commercial drug product. That means they can only be legally compounded under 503A if they are added to the 503A bulks list. That is exactly what the July 23 PCAC vote was about: whether to recommend adding them to the list.

Section 503A also imposes other constraints. A compounded drug cannot be a commercially reasonable copy of an FDA-approved drug. The pharmacist must have a valid prescription for an individual patient. The compounding must be done in a state-licensed pharmacy under state pharmacy board oversight. Certain interstate limits apply (5% of a pharmacy's compounded output can cross state lines under the default rules; more if the state has a memorandum of understanding with the FDA).

All of that is separate from the substance being on the 503A list. Being on the list is the necessary first step. Everything else is required after.

The BPC-157 vote on Thursday morning was 8-6 in favor of recommending 503A inclusion, with one abstention (one panelist did not vote either way). The KPV vote later on Thursday was identical: 8-6 in favor with one abstention.

Two things are worth noticing about the tally.

First, the vote is narrow. On a 15-member committee with one abstention, the split of the 14 voters is 8-6. That is 57% in favor, 43% against. Six panelists voted no on BPC-157. Six panelists voted no on KPV. The votes did not clear anywhere near a consensus threshold.

Second, the vote crossed the FDA staff recommendation. The FDA career-staff briefing documents, released June 29-30, recommended against adding any of the seven peptides being reviewed. The staff cited specific technical concerns: documented immunogenicity in some patients, heavy-metal and microbial contamination in compounding-channel product samples the FDA had tested, mislabeled contents in samples where advertised strength did not match analytical strength, and thin evidence of Section 503A historical use in state-licensed pharmacies.

Advisory committees frequently follow FDA staff recommendations, particularly when the staff position is anchored in analytical findings about product quality. The July 23 outcome is unusual in that respect. Reporters and legal commentators pointed to the panel composition change on June 29 (the addition of eight new members with peptide-industry ties) as a substantive factor in the crossing of the staff recommendation.

Several factors likely contributed to the 8-6 outcome.

Public comment testimony was persuasive. Hims & Hers Chief Medical Officer Dr. Anant Vinjamoori's oral testimony was reported to have moved undecided panelists. His argument was a harm-reduction case: peptides are already sold widely through gray-market channels including online vendors, wellness clinics, and (as he described) a bodega in Queens photographed by a colleague. If the FDA does not create a legal 503A pathway, that trade continues in an unregulated environment with 'no production or sourcing standards, no physician, no monitoring, and no record.' Legal 503A compounding, in that argument, is safer than the status quo even if the underlying evidence base for the peptides remains thin.

Panel composition mattered. At least seven of the eight new PCAC members named June 29 have documented ties to peptide businesses, clinics, or consulting arrangements. Coverage of the panel makeup by STAT News framed the appointment pattern as a specific choice by the current FDA leadership to seat voters more sympathetic to peptide access than the FDA career staff.

Political framing set expectations. HHS Secretary Robert F. Kennedy Jr. has publicly supported broader peptide access and has criticized the FDA's 2023 effective ban on 19 injectable peptides. That political framing shaped press coverage before the meeting and probably created a default expectation that at least some peptides would clear.

The '503A limits access to prescriptions from state-licensed pharmacies' framing may have reassured some panelists. A yes vote does not mean BPC-157 becomes available over the counter or without medical oversight. It means state-licensed pharmacists can legally prepare it under an individual prescription. Some panelists likely viewed that gate as sufficient safeguard against direct-to-consumer misuse.

On the other side, the six no votes on each peptide reflect the persistence of the FDA staff concerns. Immunogenicity, contamination, and mislabeling do not disappear because the vote passed. If BPC-157 and KPV are eventually added to the 503A list, those quality-control concerns become the responsibility of the compounding pharmacy under state board oversight and FDA inspection authority.

A close read of the vote clarifies what actually changed on July 23 and what has not changed.

The vote does not make BPC-157 or KPV legal to prescribe today. Neither substance is on the 503A bulks list as of July 23, 2026. The vote is a recommendation from the committee to the FDA. Until the FDA formally acts, the legal status of BPC-157 and KPV in the compounding channel is exactly what it was on July 22.

The vote does not authorize compounding pharmacies to prepare BPC-157 or KPV today. A pharmacy that starts compounding either substance immediately (relying on the vote as justification) would be operating outside the current 503A framework. State boards of pharmacy and the FDA retain enforcement authority. Warning letters, cease-and-desist orders, and licensure actions all remain available to regulators against compounders who move ahead of the rule.

The vote does not approve BPC-157 or KPV as commercial drug products. FDA drug approval (the process that produces a product with a New Drug Application, a label, and manufacturer marketing) is a completely separate track. Neither peptide has an approved drug application, and no company has publicly announced an intent to pursue one. A 503A listing lets compounding pharmacies work with the substance; it does not create an FDA-approved medicine.

The vote does not establish clinical efficacy or safety. The advisory committee's job is to evaluate whether a substance meets the statutory criteria for 503A inclusion, which involves considerations of historical compounding use, quality control feasibility, and appropriate labeling. It is not a substitute for randomized clinical trials. The evidence base for BPC-157 remains dominated by preclinical rodent work led by one research group, and only three human studies have been published. The evidence base for KPV is similarly limited to preclinical inflammatory bowel disease models with limited human data.

The vote does not affect telehealth access. Telehealth prescribing of peptides is a separate regulatory question involving state medical boards, DEA rules for controlled substances (which BPC-157 and KPV are not), and the individual prescriber's judgment. None of that was on the July 23 agenda.

For BPC-157 and KPV to actually become legal to compound under 503A, the FDA has to complete formal rulemaking. The process has several stages.

Stage 1: FDA leadership review of the PCAC vote. The agency reviews the committee's recommendation, evaluates whether to accept it, and identifies any modifications. This step is typically 1-3 months.

Stage 2: Proposed rule. If the FDA decides to move forward, it drafts a proposed rule that would add the substance to the 503A list. The proposed rule is published in the Federal Register and opens a public comment period (usually 60-90 days). Public commenters can raise objections, submit supporting evidence, or request modifications.

Stage 3: Response to comments and final rule. The FDA reviews all public comments and drafts a final rule. Depending on the volume and substance of comments, this can take several months. The final rule, once published, has an effective date (often 30-60 days after publication).

Stage 4: Effective date. Once the final rule takes effect, compounding pharmacies can legally prepare BPC-157 and KPV under 503A, subject to all the other 503A requirements (valid prescription, state pharmacy license, quality standards, and so on).

Total expected timeline: 6 to 18 months from the date the FDA decides to act on the vote. The lower end assumes an expedited process with minimal comment-period pushback. The upper end assumes significant public comment volume, legal challenges, or FDA staff-level dissent that requires additional review.

A counterpoint: this administration has signaled interest in moving peptide policy quickly. Whether that translates into a shorter rulemaking timeline than the historical average is uncertain and depends on FDA operational capacity, litigation from consumer-safety groups, and any change in political priorities. The 6-18 month range reflects the typical process; actual timing could vary.

And if the FDA declines to act on the PCAC vote at all, nothing changes. That outcome would be unusual but is not legally precluded. FDA acceptance is not automatic.

Cutting through the news-cycle noise, here is what pharmacies can legally do with BPC-157 and KPV as of July 24, 2026:

Compounding pharmacies cannot prepare BPC-157 or KPV for patients under Section 503A today. Neither peptide is on the 503A list. A pharmacy that dispenses either substance is operating outside the compounding framework and subject to enforcement action by state pharmacy boards and the FDA.

Federal outsourcing facilities (503B) cannot prepare BPC-157 or KPV either. Neither substance is on the 503B bulks list. The July 23 vote was about 503A only.

Physician offices cannot legally source BPC-157 or KPV from a compounding pharmacy in the US under the current framework. Physicians who prescribe either substance today are relying on gray-market vendors (research-chemical suppliers, offshore pharmacies, or unregulated wellness clinics), all of which operate outside FDA oversight.

Nothing about that changed on July 23. The legal status of BPC-157 and KPV in state-licensed compounding pharmacies today is the same as it was on July 22.

What did change: the direction of the future policy. If the FDA follows the PCAC vote and completes rulemaking, then in 6-18 months compounding pharmacies will be able to prepare BPC-157 and KPV for patients under 503A. That is a real change to the future, though it is not a change to the present.

The next several months are likely to include marketing messaging from peptide clinics, telehealth companies, and online vendors framing the PCAC vote as if it granted immediate legal access to BPC-157 and KPV. It didn't.

Questions worth asking any clinic or online vendor pitching BPC-157 or KPV in the current window:

Where is the compounded product being sourced from? If the answer is 'a state-licensed compounding pharmacy in the US,' the vendor is operating outside the 503A framework because neither peptide is on the 503A list yet. If the answer involves offshore sources, research-chemical suppliers, or unnamed 'manufacturing partners,' the product has not been through any US regulatory quality-control gate.

Has the specific batch been tested for identity, purity, and potency? The FDA career-staff briefing documents specifically flagged mislabeled contents (advertised strength not matching measured strength) and contamination (heavy metals, microbial contamination) in samples pulled from the compounding channel. Even a legitimate compounding pharmacy operating in a future 503A-legal environment will need documented batch testing.

Is there a licensed prescriber involved with an active patient-provider relationship? The 503A framework, once BPC-157 and KPV are on the list, requires an individual prescription from a licensed prescriber. A vendor that ships BPC-157 or KPV directly to consumers based on a checkbox intake form does not meet the 503A prescription requirement even if the substance is eventually listed.

What is the clinical monitoring plan? BPC-157 and KPV have thin human clinical evidence. Any legitimate prescriber offering either substance should be tracking outcomes, monitoring for adverse events, and adjusting or stopping therapy based on response. A vendor that ships product without follow-up is providing a substance, not medical care.

The PCAC meeting continues Friday July 24, 2026 at 8:00 AM ET at FDA's White Oak Campus. Day 2 covers three additional peptides:

Emideltide (delta sleep-inducing peptide, DSIP): a nonapeptide first isolated from rabbit brain in 1974. Nominated for insomnia and opioid withdrawal. FDA career-staff briefing documents recommend against inclusion, citing thin evidence and 503A historical use questions.

Semax: a synthetic heptapeptide derived from adrenocorticotropic hormone (ACTH 4-10). Developed in Russia and marketed there as a nootropic. Nominated for cerebral ischemia, migraine, and trigeminal neuralgia. FDA career-staff recommends against inclusion.

Epitalon: a synthetic tetrapeptide nominated for insomnia and anti-aging applications. Marketed heavily in wellness and longevity circles. FDA career-staff recommends against inclusion.

Given Thursday's 8-6 votes on BPC-157 and KPV, the Friday votes are likely to break in similar patterns unless individual panel members shift for peptide-specific evidence reasons. All three Day 2 substances go through the same rulemaking pipeline if they clear the vote: PCAC recommendation, FDA leadership review, proposed rule, comment period, final rule, effective date. Total timeline: 6-18 months.

Beyond the July meeting, the FDA is also expected to move on separate regulatory tracks affecting peptide access: the Trump administration's ProPublica-reported intent to reverse the 2023 effective ban on 19 injectable peptides, the pending FDA proposal to permanently exclude branded GLP-1s (semaglutide, tirzepatide, liraglutide) from the 503B list, and enforcement decisions on compounders and telehealth vendors currently operating in the gray zone. None of those tracks were on the July 23 agenda, and none was resolved by the vote.

The July 23 PCAC vote is a significant event. It is the first time an FDA advisory committee has recommended adding a popular research peptide to the 503A compounding list, and it happened over the objection of the FDA career staff who wrote the briefing documents. The political read, the stock-market read, and the mainstream media framing are all reasonable in their own frame: the vote signals a directional shift in federal peptide policy.

What did not change: BPC-157 and KPV are not legal to compound under 503A today. Pharmacies cannot prepare either substance for patients under the compounding framework yet. Prescribers cannot legitimately source either substance from a US compounding channel. Patients considering BPC-157 or KPV in July 2026 are still choosing between an unregulated gray market on one hand and waiting for FDA rulemaking to complete on the other.

The realistic timeline for legal 503A access is 6-18 months from the date the FDA acts on the vote. Vendors and clinics marketing 'legal peptides now' on the strength of the vote alone are moving faster than the regulatory process supports.

On the other hand, the direction is now clear. Barring an FDA decision to reject the vote (unusual, but legally possible), BPC-157 and KPV are likely on a path to 503A inclusion within the next 6-18 months. Patients, physicians, and pharmacies that want to work with those substances legally can prepare now for a future in which the compounding pathway becomes available, without treating today's vote as if it has already delivered that future.

The evidence base itself is not on that timeline. Human clinical trial evidence for BPC-157 remains limited to three published human studies dominated by one research group. Human clinical trial evidence for KPV remains dominated by preclinical models with limited human data. A 503A listing does not create new clinical evidence. It creates a legal pathway for a substance whose clinical case will continue to be made or unmade on the strength of future trials, which nobody has yet publicly committed to running at scale.